• Li Wang, Hong Cheng, Xue Wang, and Linmei Zheng.
• Department of Obstetrics, Hainan People's Hospital.
• Medicine (Baltimore). 2021 Apr 30; 100 (17): e25673e25673.

Background:The existing meta-analyses and randomized studies on myoinositol are of poor quality, with small sample sizes, and involve a homogeneous population. The general applicability of these findings to the National Health Service is unclear. We thus conduct this new high-quality systematic review and meta-analysis to assess the efficacy and safety of myoinositol in pregnant woman.Methods:The study protocol will be developed and executed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. All of the following inclusion criteria in the PICOS order will be met by the studies included in our meta-analysis: 1. population: pregnant woman without gestational diabetes mellitus (GDM); 2. intervention: group with myoinositol; 3. comparison intervention: group without myoinositol; 4. outcome measures: at least one of the following outcome measures should to be reported: rate of GDM, offspring birthweight, fasting glucose, oral glucose tolerance test, and the side effects associated with the myoinositol; and 5. study design: English randomized trials. The following electronic databases will be searched: PubMed, Scopus, EMBASE, and Cochrane Library databases. The Cochrane risk of bias tool will be used to evaluate the risk of bias of the included randomized trials by 2 independent reviewers.Results:We will perform a meta-analysis using standard techniques for the outcomes.Conclusions:It was hypothesized that myoinositol supplementation could increase the action of endogenous insulin and prevent GDM and its complications.Trial Registration:10.17605/OSF.IO/9W8DV.

18 keywords...

hide…